Du är här

2015-10-01

FIT Biotech Oy: Notice convening an extraordinary general meeting of FIT Biotech Oy

FIT Biotech Oy

Company Release, October 1, 2015 at 9:00 EET

Notice convening an extraordinary general meeting of FIT Biotech Oy

The shareholders of FIT Biotech Oy are invited to an extraordinary general
meeting, which is to be held on Thursday, 22 October 2015 starting at 12:00
noon at the offices of Castrén&Snellman Attorneys Ltd at Eteläesplanadi 14
(6th floor), 00130 Helsinki, Finland. The reception of persons who have
registered for the meeting will begin at 11:30.

A. Matters on the Agenda of the General Meeting

At the general meeting, the following matters will be considered:

1 Opening of the meeting
2 Calling the meeting to order
3 Election of persons to scrutinise the minutes and to count the votes
4 Recording the legality of the meeting
5 Recording the attendance at the meeting and adoption of the list of votes
6 Resolution on the number of the members of the board of directors The board
of directors proposes to the general meeting that the number of members of
the board of directors be confirmed as six (6).

1 Election of members of the board of directors The board of directors
proposes to the general meeting that Tomi Numminen and Rabbe Klemets be
elected as new members of the board of directors and that current members
of the board Rabbe Slätis, Erkki Pekkarinen, Dirk Teuwen and Juha
Vapaavuori be re-elected as members of the board of directors for a term of
office that expires at the end of the first annual general meeting
following the election. All candidates have consented to being re-elected.

1 Closing of the meeting

B. Documents of the General Meeting

The aforementioned proposals for resolutions on the matters on the agenda of
the general meeting as well as this notice are available on FIT Biotech Oy's
website at the addresswww.fitbiotech.comand at the head office at the latest
as of 1 October 2015. The documents of the general meeting are also available
at the general meeting and copies will be delivered to shareholders upon
request. The minutes of the general meeting will be available on the
company's website and at the head office at the latest as of 5 November 2015.

C. Instructions for the Participants in the General Meeting

1. Shareholders Registered in the Shareholders' Register

Each shareholder who is registered on 12 October 2015 in the shareholders'
register of the company held by Euroclear Finland Ltd has the right to
participate in the general meeting. A shareholder whose shares are registered
on his/her personal Finnish book-entry account is registered in the
shareholders' register of the company.

A shareholder who is registered in the shareholders' register of the company
and who wants to participate in the general meeting has to register for the
meeting no later than on 19 October 2015 at 10:00 a.m. by e-mail to the
addressliisa.laitinen@fitbiotech.comor by post to the address FIT Biotech
Oy/Liisa Laitinen, Biokatu 8, 33520 Tampere, Finland, by which time the
registration must be received by the company. The shareholder's name and
personal identification number or business ID, address, telephone number as
well as the name of a possible assistant or proxy representative and the
personal identification number of a proxy representative must be provided in
connection with the registration. The personal data provided by the
shareholders to the company is only used in connection with the general
meeting and with the necessary processing of related registrations.

The shareholder, his/her authorised representative or proxy representative
must, if necessary, be able to prove his/her identity and/or right of
representation at the general meeting.

2. Holders of Nominee Registered Shares

A holder of nominee registered shares has the right to participate in the
general meeting based on the shares that would entitle him/her to be
registered in the shareholders' register held by Euroclear Finland Ltd on 12
October 2015. In addition, the right to participate requires that holders of
nominee registered shares be temporarily entered into the shareholders'
register held by Euroclear Finland Ltd based on these shares by 19 October
2015, 10:00 a.m., at the latest. As regards nominee registered shares this
constitutes due registration for the general meeting.

A holder of nominee registered shares is advised to request without delay
necessary instructions regarding the registration in the temporary
shareholder's register of the company, the issuing of proxy documents and
registration for the general meeting from his/her custodian bank. The account
operator of the custodian bank has to temporarily register a holder of
nominee registered shares who wants to participate in the general meeting
into the shareholders' register of the company at the latest by the time
stated above.

3. Proxy Representatives and Powers of Attorney

A shareholder may participate in the general meeting and exercise his/her
rights at the meeting by way of proxy representation. A proxy representative
must produce a dated proxy document or otherwise in a reliable manner
demonstrate his/her right to represent the shareholder at the extraordinary
general meeting. When a shareholder participates in the general meeting by
means of several proxy representatives representing the shareholder with
shares in different securities accounts, the shares by which each proxy
representative represents the shareholder must be identified in connection
with registration for the general meeting. Any proxy documents and powers of
attorney are requested to be delivered by post to the address FIT Biotech
Oy/Liisa Laitinen, Biokatu 8, 33520 Tampere, Finland or by e-mail to the
addressliisa.laitinen@fitbiotech.comat the latest on 19 October 2015.

Tampere 1 October 2015

FIT Biotech Oy

Board of directors

Additional information:

CEO Kalevi Reijonen, FIT Biotech Oy
Email:kalevi.reijonen@fitbiotech.com

Phone: +358 40 843 5695

Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790

FIT Biotech Oy in brief:

FIT Biotech Oy is a biotechnology company established in 1995, focusing on DNA
vaccines and gene therapy. The company bases its products on its patented GTU
® (Gene Transport Unit) technology.

Through GTU technology, FIT Biotech develops DNA vaccines in order to both
prevent and also treat various diseases. Identified application areas include
HIV, tuberculosis (and other infectious diseases) as well as gene therapy
(cancer, autoimmune diseases). Other application areas are under development.

FIT Biotech Oy is listed on NASDAQ First North (ticker: FITBIO). More
information can be found atwww.fitbiotech.com.

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: FIT Biotech Oy via Globenewswire

HUG#1955856

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.